Palmitoyl Tripeptide-5 (SYN-COLL) Dosage Protocol

Quickstart Highlights

Palmitoyl Tripeptide-5 is a cosmetic lipopeptide: the three-amino-acid chain Lys-Val-Lys with a sixteen-carbon palmitic acid tail on the N-terminus. PubChem lists it as CID 11950477, molecular formula C₃₃H₆₅N₅O₅, molecular weight 611.9 g/mol^[1], and its IUPAC name resolves the structure explicitly as a hexadecanoyl group on lysine, then valine, then lysine — palmitoyl-K-V-K. A vendor selling it as a 200 mg powder lists the same formula, the same weight and the same sequence independently^[9]. The trade name most people know it by is SYN-COLL, and CAS 623172-56-5 comes from the originator’s own dossier^[2].

That dossier is also where this ingredient goes wrong. SYN-COLL is not the peptide: it is a glycerin-based aqueous solution of it, and DSM’s composition table puts the peptide at 0.1–1% of the material, with glycerin above 50% and water at 25–50%^[2]. Every percentage quoted for this ingredient — including the recommended use level — refers to that solution. Applying the same number to the >99% powder sold in 200 mg vials changes the amount of peptide by two to three orders of magnitude. Getting that one relationship straight is what this page is for.

Supplies Needed

This is a cosmetic raw material, not a research vial, and nothing about it is reconstituted or injected. Two vendors checked on 11 August 2026 sell it as a 200 mg lyophilized powder described as >99% purity, listing the sequence as Palmitoyl-Lys-Val-Lys with formula C₃₃H₆₅N₅O₅ and molecular weight 611.9^[9] — matching the PubChem record independently^[1]. Neither states a solvent or a use level for the powder. What you need is a formulation to put it in, a way to measure single-digit milligrams accurately, and a certificate of analysis.

Palmitoyl Tripeptide-5

View Supplier

Protocol Overview

The design rationale is thrombospondin-1, and it is worth stating exactly. Thrombospondin-1 releases active TGF-beta from its latent complex, and the sequence responsible was mapped to K₄₁₂RFK₄₁₅, which interacts with an LSKL sequence on the latency-associated peptide^[4]. SYN-COLL is marketed as mimicking that mechanism. Its sequence, however, is K-V-K, not KRFK — the resemblance is a design argument, not an identity.

The peer-reviewed foundation for this class used a different tripeptide. The 2004 paper that introduced a thrombospondin-like lipopeptide synthesised elaidyl-KFK and showed it activated latent TGF-beta1, raised collagen and TIMP-1, suppressed PMA-induced MMP-1, and inhibited MMP-1, 2, 3 and 9 in vitro^[3]. In the same experiments KQK and KQFK were inactive, including as lipopeptides — so activity in this family is sequence-sensitive, and small changes abolish it. That paper did not test K-V-K, which means the published evidence neither supports nor refutes the exact sequence SYN-COLL uses.

Independent review says the quiet part out loud. A 2021 analysis of 88 marketed facial cosmetics found palmitoyl tripeptide-5 among seven peptides in use, and concluded that for these ingredients the available data is “mostly found in patents and supplier brochures, and not in randomized placebo-controlled studies”^[6]. That is the honest frame for every efficacy number attached to this molecule.

It sits in a cluster where the same mistake keeps happening. The percentage trap on this page is the fourth we have documented on a cosmetic peptide: the famous number for Biotinoyl Tripeptide-1 belongs to Procapil rather than the peptide, and SYN-AKE and Palmitoyl Tetrapeptide-7 are sold in the same 200 mg powder format with the same ambiguity. If you are formulating from any of them, read the material behind the percentage before the percentage.

Dosing Protocol

Reference conversions only. Each row starts from a concentration of peptide in the finished product, works out the mass a 100 g batch would need, and states what a single 200 mg vial covers. The first three rows are the manufacturer’s documented band; the last two are what happens when a percentage written for the glycerin solution is applied to raw powder.

Dosing & Application

Palmitoyl Tripeptide-5 is applied to the skin inside a finished formulation, so the only quantity with a documented basis is the concentration of peptide in that formulation. Three different materials circulate under the same name — the >99% powder, the SYN-COLL glycerin solution, and the finished cream — and the same percentage means something different against each one.

Standard / Gradual Approach

The manufacturer’s figure, and what it actually refers to. DSM’s formulation guidelines give the use level as 1–3% SYN-COLL for skin care preparations, and the composition table on the same document lists the material as palmitoyl tripeptide-5 at 0.1–1%, glycerin above 50% and water at 25–50%^[2]. Neat SYN-COLL is therefore about 1,000–10,000 ppm of peptide, and a product made to the recommended use level contains 10–300 ppm. The range is wide because the supplier declares a range, not because the arithmetic is uncertain.

The manufacturer’s own test cream pins it down further. The dossier prints the full formula of the nourishing cream used for its in-vivo study, and SYN-COLL appears in phase A at 2.50% w/w, alongside 5% glycerin, in an emulsion adjusted with sodium hydroxide^[2]. At 2.5% of a 0.1–1% material, that cream carried roughly 25–250 ppm of peptide. If you want to reproduce what the supplier actually tested, that is the band to aim at — not 2.5% of powder.

The raw powder is a third material, and the trap closes here. Vendors sell palmitoyl tripeptide-5 as a lyophilized powder at >99% purity in 200 mg vials^[9]. Taking the 3% instruction and applying it to that powder gives 30,000 ppm — between 100 and 3,000 times the level DSM’s own recommendation produces. The physical check is blunt: a 100 g batch at 3% powder needs 3 g, which is fifteen entire 200 mg vials. If a formulation percentage would consume fifteen vials for one small jar, the percentage is describing something else.

The practical consequence: weigh it, or make a stock solution. A 100 g batch at 100 ppm needs 10 mg of powder, which a milligram balance can read; at 10 ppm it needs 1 mg, which most cannot read reliably. The working method for the low end is a stock solution — 200 mg into 20 mL gives 10 mg/mL, so 1 mg is 100 µL and 10 mg is 1.0 mL. Note that the commercial material is supplied pre-dissolved in glycerin and water for exactly this reason, and suppliers of the neat powder do not state a solvent^[9].

Storage Instructions

The manufacturer’s storage figures describe the solution, not your powder. DSM states that SYN-COLL keeps for at least 36 months from manufacture in the unopened original container, protected from light, in a clean place, at 2–8 °C, and that once opened the contents should be used quickly to avoid secondary microbial contamination^[2]. That is a glycerin-water solution. A lyophilized powder is a different physical form with its own batch-specific shelf life on its certificate of analysis.

Store the powder cool, dry, dark and tightly closed, and treat the certificate of analysis as the authority on its expiry rather than a figure quoted for the trade material. Lyophilized peptides are hygroscopic; repeated warming and opening is what degrades them.

A stock solution has its own shelf life. If you make one in order to measure milligram amounts, an unpreserved aqueous peptide solution is a growth medium. It needs a preservative system and a date on the bottle, and once the peptide is in a finished product it is that product’s preservation, not the peptide’s, that governs.

Important Notes

These are the points that vanish once this ingredient reaches a marketing page.

• ▪The single most important correction on this page. “Use at 1–3%” is a DSM instruction about SYN-COLL, a glycerin solution that is 0.1–1% peptide^[2]. The peptide concentration that instruction produces is 10–300 ppm. A formulation using 3% raw powder is not following the manufacturer — it is at one hundred to three thousand times the level the manufacturer’s own recommendation delivers.
• ▪The one measurement of whether it gets into skin is discouraging. A 2023 study loaded two cosmetic peptides into supramolecular hydrogels and ran them through Franz diffusion cells with HPLC-MS quantification. Trifluoroacetyl tripeptide-2 permeated in a considerable amount; for palmitoyl tripeptide-5, “almost no transdermal permeation” was observed^[5]. It is one vehicle and one model, but it is the only peer-reviewed permeation number this molecule has, and it runs against the usual claim that the palmitoyl tail carries it through the stratum corneum.
• ▪The 2024 nanoparticle paper is evidence of the same problem, read the right way. Researchers encapsulated palmitoyl tripeptide-5 in lactoferrin and recombinant collagen nanoparticles specifically to improve delivery, and reported transdermal efficiency improved by 69.90% versus the unencapsulated form^[8]. A carrier that improves delivery by seventy per cent is a measurement of how poorly the bare peptide was getting in.
• ▪Every positive human-facing result tested a mixture. The 12-week microneedle-patch study reporting a 25.8% decrease in fine lines used hyaluronic acid patches loaded with an arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts — five actives plus a microneedle delivery system^[7]. The nanoparticle study is likewise a multi-component formulation with commercial affiliations^[8]. Neither isolates this peptide.
• ▪Widely circulated wrinkle percentages have no source I could verify. Figures such as “45 volunteers, 1% and 2.5%, 7% and 12% wrinkle reduction” and “4% cream, 35% less wrinkle depth” appear on resale and blog pages without a traceable study. They are not cited here. Note also that a 4% figure sits outside DSM’s own 1–3% recommended range^[2], which is a reason to doubt the provenance rather than to raise the dose.
• ▪Formulation constraints are real and specific. DSM gives a recommended final-product pH of 3.0–7.0, compatibility with up to 50% ethanol, incorporation into the aqueous phase, processing cold or warm up to two hours at 80 °C but with addition at the end of the process below 40 °C still recommended — and warns that SYN-COLL “usually precipitates if diluted with excess of water”, a precipitate the dossier says does not affect activity and disappears once an oil phase is added^[2].
• ▪It is a cosmetic ingredient, and the claims should stay cosmetic. There is no FDA approval, no drug indication and no controlled trial of the molecule alone. Comparisons to injectable or prescription treatments have no basis in the published record.

How This Works

The proposed pathway is TGF-beta activation, borrowed from thrombospondin-1. Latent TGF-beta circulates bound to its latency-associated peptide; thrombospondin-1 releases the active cytokine, and the interaction was localised to the KRFK sequence on thrombospondin-1 and LSKL on the LAP^[4]. Active TGF-beta then signals fibroblasts to lay down collagen. SYN-COLL is positioned as a small synthetic stand-in for that trigger. That is a different route to collagen from the two best-known peptides in this category: GHK-Cu works through copper delivery and matrix signalling, and Matrixyl 3000 through matrikine fragments, while Argireline does not target collagen at all.

The MMP side of the story comes from the lipopeptide, not the peptide. In the 2004 work, the fatty-acyl tripeptide inhibited MMP-2, MMP-9, MMP-3 and MMP-1 with IC₅₀ values of 1.2, 1.0, 0.24 and 8.9 µM respectively, and at 1 µM cut the elastin-degrading activity of MMP-9 in skin sections by up to 80%^[3]. The authors attributed the protease inhibition to the lipophilic moiety and the TGF-beta activation to the peptide domain — two separate contributions from the two halves of the molecule.

What that paper does not license is a claim about K-V-K. Its active compound was elaidyl-KFK, and KQK and KQFK — both close analogues — were inactive in the same assays^[3]. The honest position is that this class demonstrably works only for the sequences that were tested, that SYN-COLL uses a sequence which was not among them, and that the supporting data for K-V-K specifically lives in supplier documents rather than in the peer-reviewed literature^[6].

None of it matters if the molecule stays on the surface. Mechanism arguments assume delivery to the dermal fibroblast. The one published permeation measurement on this peptide found almost none crossing^[5], and the strongest delivery result in the literature came from wrapping it in a nanoparticle carrier^[8]. Formulation, not concentration, is the open question here.

Lifestyle Factors

Judge a collagen-signalling ingredient on a collagen timescale. Dermal remodelling is measured over months, not weeks; the microneedle study ran 12 weeks and the nanoparticle study 28 days for hydration but longer for structural endpoints^[7][8]. Anything assessed at two weeks is measuring hydration and light reflection from the vehicle.

The vehicle does a lot of the work, and glycerin is in the room. The trade material is more than half glycerin, and the manufacturer’s test cream added a further 5% glycerin on top^[2]. Glycerin is an effective humectant with visible short-term effects on skin appearance, which is precisely why an uncontrolled before-and-after on a peptide serum is weak evidence about the peptide.

Sun exposure outranks the ingredient. Ultraviolet exposure induces the matrix metalloproteinases this peptide is claimed to inhibit. Daily photoprotection is the intervention with the strongest evidence for preserving dermal collagen, and no cosmetic peptide substitutes for it.

Potential Benefits & Side Effects

Evidence tier: manufacturer dossier and in-vitro work, plus small multi-ingredient clinical studies; nothing at all on the peptide alone. Each reported effect below is listed with the material that was actually tested attached to it, because that is the distinction the marketing removes. This is a cosmetic ingredient with no FDA approval, and no study below tested palmitoyl tripeptide-5 by itself.

How to Apply

There is nothing to reconstitute and nothing to inject. What follows is the workflow for turning a 200 mg powder into a finished topical at a concentration with a documented basis, and for judging the result honestly. It is educational reference, not a formulation service or medical advice.

Skin Preparation

• ▪Confirm the identity before anything else. The checks are PubChem CID 11950477, formula C₃₃H₆₅N₅O₅, MW 611.9^[1], sequence Palmitoyl-Lys-Val-Lys, CAS 623172-56-5^[2]. Vendor listings checked stated >99% purity as a lyophilized powder^[9]. Ask for the batch certificate rather than accepting the catalogue description.
• ▪Establish which material your percentage refers to. The >99% powder, the SYN-COLL glycerin solution at 0.1–1% peptide, and the finished cream are three different things. Write down which one you have before doing any arithmetic.
• ▪Pick the target from the table, not from a forum. The documented band is 10–300 ppm of peptide in the finished product, and the manufacturer’s own study cream sat at roughly 25–250 ppm^[2].

Applying the Product

• ▪Work out the mass, then decide whether you can weigh it. A 100 g batch needs 1 mg at 10 ppm, 10 mg at 100 ppm and 30 mg at 300 ppm. Below about 5 mg, use a stock solution — 200 mg into 20 mL gives 10 mg/mL, so 1 mg is 100 µL by pipette.
• ▪Add it to the aqueous phase, late and cool. DSM directs SYN-COLL into the water phase, tolerates cold or warm processing up to two hours at 80 °C, and still recommends addition at the end of the production process below 40 °C^[2].
• ▪Keep the final pH between 3.0 and 7.0, adjusting with common neutralising agents, and expect possible precipitation if the material is diluted into excess water before the oil phase goes in^[2].
• ▪Do not scale the number up to feel like a dose. Ten to three hundred parts per million looks like nothing on a balance, and that is exactly the band the manufacturer built its own test cream and its recommendation around. The concentration is small because the material it was written for is dilute.

After Application

• ▪Give it three months before judging it. The controlled cosmetic studies in this space run 12 weeks for structural endpoints^[7]. Earlier assessments are measuring hydration from glycerin and the rest of the vehicle.
• ▪Attribute results honestly. If the formula also contains acetyl octapeptide-3, hyaluronic acid, adenosine or a microneedle patch, the published record says those combinations worked as combinations^[7][8] — and gives you no way to credit this peptide specifically.
• ▪Treat delivery as the unresolved question. The single peer-reviewed permeation measurement on this peptide found almost none crossing skin^[5], and the best delivery result in the literature required a nanoparticle carrier^[8]. Raising the concentration does not solve a penetration problem.
• ▪Keep the regulatory position straight. This is a cosmetic ingredient with no approval to treat anything, whose human evidence base is small, multi-ingredient and largely industry-linked^[6]. Treat it as an optional addition to a skincare routine, never as a treatment.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for Palmitoyl Tripeptide-5 (200 mg).

References

1. 1
   PubChem CID 11950477 — Palmitoyl Tripeptide-5. National Center for Biotechnology Information.

   The chemical identity record: molecular formula C₃₃H₆₅N₅O₅, molecular weight 611.9 g/mol. The IUPAC name resolves the structure as a hexadecanoyl (palmitoyl) group on lysine, joined to valine and then to a second lysine — palmitoyl-Lys-Val-Lys. Retrieved 11 August 2026.

   View Source ↗

2. 2
   DSM Nutritional Products / Pentapharm — SYN®-COLL formulation guidelines (technical dossier)

   The originator’s own document and the primary source for every concentration on this page. Its composition table lists Palmitoyl Tripeptide-5 at 0.1–1%, Glycerin above 50% and Aqua at 25–50%, with CAS 623172-56-5. Under “Use level” it states: “For skin care preparations a concentration of 1–3% SYN-COLL is recommended.” It gives a recommended final-formulation pH of 3.0–7.0, compatibility with up to 50% ethanol, incorporation into the aqueous phase with addition below 40 °C at the end of the process, storage at 2–8 °C for at least 36 months, and warns that the material usually precipitates if diluted with excess water. It also prints the full formula of the nourishing cream used for its in-vivo anti-wrinkle study, in which SYN-COLL appears at 2.50% w/w. A manufacturer dossier, not a peer-reviewed publication. Retrieved and text-extracted 11 August 2026.

   View Source ↗

3. 3
   Biochemical Pharmacology (2004) — Activation of latent transforming growth factor beta 1 and inhibition of matrix metalloprotease activity by a thrombospondin-like tripeptide linked to elaidic acid

   Cauchard, Berton, Godeau, Hornebeck & Bellon (PMID 15135298). The founding peer-reviewed paper for this class of cosmetic lipopeptide. Elaidyl-KFK activated LAP-TGF-beta in a solid-phase assay and in human dermal fibroblast cultures, up-regulated collagen and TIMP-1, down-regulated PMA-induced MMP-1, and inhibited MMP-2, MMP-9, MMP-3 and MMP-1 with IC50 values of 1.2, 1.0, 0.24 and 8.9 µM. Critically for this page, KQK and KQFK, along with their lipopeptide counterparts, were inactive — activity is sequence-sensitive. The tested sequence is K-F-K; SYN-COLL is K-V-K, which this paper did not test. DOI: 10.1016/j.bcp.2004.01.028.

   View Source ↗

4. 4
   Journal of Biological Chemistry (1999) — The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta

   Ribeiro, Poczatek, Schultz-Cherry, Villain & Murphy-Ullrich (PMID 10224129). Establishes that thrombospondin-1 activates latent TGF-beta through a specific sequence, K412RFK415, interacting with an LSKL sequence near the amino terminus of the latency-associated peptide. This is the mechanism SYN-COLL is marketed as mimicking, and the reference that makes clear the mimicry is by design intent rather than by sequence identity. DOI: 10.1074/jbc.274.19.13586.

   View Source ↗

5. 5
   Molecules (2023) — Delivery of Active Peptides by Self-Healing, Biocompatible and Supramolecular Hydrogels

   Shariati Pour et al. (PMID 36985499). Two cosmetic peptides were loaded into supramolecular hydrogels and their transdermal permeation measured with Franz diffusion cells and HPLC-MS. Trifluoroacetyl tripeptide-2 permeated in a considerable amount, while “almost no transdermal permeation of Palmitoyl tripeptide-5 was observed”. One vehicle and one model, but the only peer-reviewed permeation measurement this molecule has, and it cuts against the claim that the palmitoyl tail drives penetration. DOI: 10.3390/molecules28062528.

   View Source ↗

6. 6
   Pharmaceuticals (2021) — Usage of Synthetic Peptides in Cosmetics for Sensitive Skin

   Resende, Ferreira, Sousa-Lobo, Sousa & Almeida (PMID 34451799). Analysed 88 facial cosmetics for sensitive skin from multinational brands. Peptides appeared in 17% of products, palmitoyl tripeptide-5 among the seven identified. The review states that only five of the seven have any evidence supporting use in sensitive skin, with a single clinical study including volunteers with the condition, and that the available data is “mostly found in patents and supplier brochures, and not in randomized placebo-controlled studies”. DOI: 10.3390/ph14080702.

   View Source ↗

7. 7
   Journal of Cosmetic Dermatology (2019) — Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study

   Avcil, Akman, Klokkers, Jeong & Çelik (PMID 31134751). Twelve-week monocentric study of hyaluronic acid microneedle patches containing arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts, applied at the outer eye corners and volar forearm. Reported a 25.8% decrease in fine lines and wrinkles, 15.4% better hydration, and dermal density and thickness up 14.2% and 12.9%, with no primary or cumulative skin reactions. Five actives plus a microneedle delivery system, with author affiliations to the companies involved — no result here is attributable to palmitoyl tripeptide-5 alone. DOI: 10.1111/jocd.13009.

   View Source ↗

8. 8
   Colloids and Surfaces B: Biointerfaces (2024) — Supramolecular collagen nanoparticles for anti-wrinkle, skin whitening, and moisturizing effects

   Chen et al. (PMID 39383579). Lactoferrin and recombinant human collagen were used as carriers encapsulating palmitoyl tripeptide-5 at 94.18% encapsulation. Reported transdermal efficiency improved by 69.90%, and over 14 to 28 days: stratum corneum moisture up 10.51%, facial elasticity up 8.15%, firmness up 12.53%, eye-bag wrinkles down 24.69% and nasolabial wrinkles down 37.61%. The tested article is the nanoparticle system rather than the peptide, two authors are affiliated to a commercial biotechnology company, and the stated purpose of the carrier — improving penetration — is itself evidence about how poorly the bare peptide crosses skin. DOI: 10.1016/j.colsurfb.2024.114275.

   View Source ↗

9. 9
   Vendor product listings for SYN-Coll / Palmitoyl Tripeptide-5, 200 mg topical (Core Peptides; Biotech Peptides), retrieved 11 August 2026.

   Independent listings establishing how the raw material is actually sold to the reader of this page: a 200 mg lyophilized powder stated at >99% purity, sequence given as Palmitoyl-Lys-Val-Lys with molecular formula C33H65N5O5 and molecular weight 611.9 g/mol — matching the PubChem record independently. Both are marked for research and laboratory use only and not for human consumption. Neither states a solvent, a reconstitution volume or a use level for the powder, which is the gap this page exists to fill.

   View Source ↗